Navigation Links
Statement from the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose
Date:12/14/2007

WASHINGTON, Dec. 14 /PRNewswire-USNewswire/ -- Following is a statement by Linda A. Suydam, D.P.A., president of the Consumer Healthcare Products Association (CHPA), regarding the recommendations of the U.S. Food and Drug Administration's Nonprescription Drugs Advisory Committee on phenylephrine:

"Phenylephrine 10 mg is safe when used according to the label and has been proven effective for nasal decongestion in multiple clinical trials. Today, the FDA's expert panel voted almost unanimously [11-1] that the existing evidence supports the effectiveness of phenylephrine at the 10 mg dose and reaffirms the results of numerous scientific studies and decades of consumer experience.

"CHPA and the leading makers of OTC cough, cold, and allergy medicines containing phenylephrine are committed to adding to the existing body of evidence currently supporting the safety and efficacy of phenylephrine. Our goal is to continue to provide consumers with safe and effective therapies, and we are committed to working with FDA to ensure that the scientific data further supports this goal.

"Consumers should remain confident that phenylephrine 10mg provides safe and effective relief from nasal congestion due to the common cold and allergies and that this FDA-approved nasal decongestant will remain conveniently available over-the-counter.

"For over forty years, consumers worldwide have relied upon phenylephrine to give them much needed relief from nasal congestion caused by the common cold and allergies. We look forward to working with FDA staff as they review the recommendations of today's panel. We will continue our commitment to ensure that consumers have access to safe and effective over-the-counter therapies.

CHPA is the 126-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and nutritional supplement products.

http://www
'/>"/>

SOURCE Consumer Healthcare Products Association
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations
2. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
3. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
4. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
5. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
6. Statement by Oscar S. Wyatt, Jr.
7. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
8. Pelosi Statement on Proposed Entitlement Task Force
9. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
10. Statement on House/Senate Agreement on SCHIP Legislation
11. Statement from the Alliance for Quality Nursing Home Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)... Improve Your Child,s Comfort and Performance duri...wswire/ -- The Good Feet Stores, a,California base...ports and,natural sponge rubber cushions, announce...rts designed specifically for children ages 6 and ... the "SportFlex," are now,currently available at p...
(Date:5/13/2008)...ATLANTA, May 13 /PRNewswire/ -- Annually, allergie...s, causing untold suffering, sneezing and,wheezing...ication., However, putting the right air treatmen... home can create a healthier living environment an...home health specialist and,president of Sylvane.co...
(Date:5/12/2008)...YOKNEAM, Israel, May 13 /PRNewswire/ -- Lumenis In... laser, light-based and radiofrequency,devices for... announced,today the launch of a Holmium Laser Enu... that will provide training opportunities for urol...ng HoLEP. The abundance of,clinical evidence sugge...
(Date:5/12/2008)...DIANAPOLIS A study published in the May/June issue... trial providing a scientifically valid look at wh...t programs that serve low-income individuals. The ... leaders struggling to meet the needs of individua...some disease management efforts, even among relati...
Breaking Medicine News(10 mins):Health News:Good Feet Announces New Arch Support Product Line for Children Ages 6 and Older 2Health News:Simple Steps to a Healthier, Allergy-Free Home 2Health News:Simple Steps to a Healthier, Allergy-Free Home 3Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Chronic disease management: Does it improve health and save money? 2
... was so fazed-out when she was addicted to crystal...he used to talk to a basket . The Black Eyed Peas'...nking someone was sitting inside it, and would com...member thinking somebody was inside of it, going t...
...t of Madhya Pradesh has banned the use of vibratin... The state-run Hindustan Latex Limited (HLL) intro...months ago. Protesting its launch, Hindu hardlin...bed the condom was a sex toy going against Indian ...
...n worldwide appears to be slowing down for almost ...ice on Drugs and Crime said on Friday. "Some obvi...ghanistan, a cancer that threatens security and h...C executive director Antonio Maria Costa, ahead of...
...th sector crisis deepened Friday as pay talks brok... country's nurses, hundreds of whom are camping ou...s, which had been planned for the early hours of F... ground after each side accused the other of bad f...
Other Medicine News:Health News:Drug Addiction Slowing Down: UN Report 2Health News:Talks Break Down in Polish Nurses' Pay Protest 2
(Date:5/12/2008)... 12 /- GeoVax Labs, Inc. (O...DS vaccine development,company, announced today th...purchase agreement with Fusion Capital Fund II, LL...ompany may sell up to $10 million of its common st...month period after the Securities and,Exchange Com...
(Date:5/12/2008)...romising neurological recovery in severely-injured... treated with Cethrin, HOPKINTON, Mass., May 12 /...Inc. (Nasdaq: ALSE ) today announced 12-month int...ethrin, a proprietary recombinant,protein that is ...tor and,sensory function after spinal cord injury,...
(Date:5/12/2008)...Phase 1 Clinical Data of MDX-1100 at Digestive Dis...PRINCETON, N.J., May 12 /- ...t it has initiated the Phase 2 clinical,developmen...tibody that,targets CXCL10 (also known as IP-10), ...s (RA). MDX-1100 could potentially treat UC and RA...
(Date:5/12/2008)...in Cohort 3 Demonstrated Improvement in T-Cell Res...Potential of HspE7, SAN DIEGO, May 12 /PRNewswire...on (TSX: NVN) today announced positive immunologic... 1 clinical trial of its lead product,candidate, H...oplasia, or,CIN, a precursor to cervical cancer. H...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 5Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 2Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 3Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Allergy Induced Asthma More Common in Affluent Countries 1377 1Allergy Induced Asthma More Common in Affluent Countries 1377 2Allergy Induced Asthma More Common in Affluent Countries 1377 3IMPACT initiative looks to improve patient participation in clinical trials 1372 1IMPACT initiative looks to improve patient participation in clinical trials 1372 2VirtualScopics Announces 244 35 Million Private Placement 1369 1VirtualScopics Announces 244 35 Million Private Placement 1369 2VirtualScopics Announces 244 35 Million Private Placement 1369 3Pathway Diagnostics Announces Commercial Availability of SensiTrop 28TM 29 HIV Co receptor Tropism Assay 1364 1Pathway Diagnostics Announces Commercial Availability of SensiTrop 28TM 29 HIV Co receptor Tropism Assay 1364 2Pathway Diagnostics Announces Commercial Availability of SensiTrop 28TM 29 HIV Co receptor Tropism Assay 1364 3
..., Ltd. Sponsored Study,Presented at the American P..., May 23, 2007 /PRNewswire/ -- In a six-week study...nia, the Otsuka,Pharmaceutical Co., Ltd. and Brist...piprazole demonstrated significant improvement,com... Positive and,Negative Syndrome Scale (PANSS) Tota...
...ith Monoclonal Antibody,Targeting Interleukin-9 (I...or IL-9 Inhibition in Developing Potential Asthma,...wire-FirstCall/ --,MedImmune, Inc. today announced...ress within the company,s inflammatory,disease pip...,studies with its monoclonal antibody (MAb) target...
Other Medicine Technology:Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 2Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 3Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 4Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 5Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 6Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 7Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 8Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 9MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity.
It is lightweight and portable headlight option for office exam room. It offers complete comfort and portability.
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost.
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband.
Medicine Products: